杨子菁

Cooley advised D3 Bio – an emerging global biotechnology company that focuses on discovery, development and registration of innovative cancer drugs – on the close of its $62 million Series A+ financing.

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its $112 million oversubscribed Series B financing.

Cooley advised NeuExcell Therapeutics, a neurodegenerative disease gene therapy company, on its $15 million+ Series Pre-A+ financing round.

Cooley advised SJ Semiconductor Corporation (SJSemi), a semiconductor foundry, on its $340 million Series C+ financing, with a post-money valuation of close to US$2 billion.